阿比特龙和己烯雌酚序贯给药治疗去势抵抗性前列腺癌的抗肿瘤活性。
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.
机构信息
Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.
出版信息
Br J Cancer. 2013 Sep 3;109(5):1079-84. doi: 10.1038/bjc.2013.446. Epub 2013 Aug 8.
BACKGROUND
Abiraterone is a standard treatment for men with castration-resistant prostate cancer (CRPC). We evaluated the antitumour activity of abiraterone following the synthetic oestrogen diethylstilboestrol (DES).
METHODS
Castration-resistant prostate cancer patients treated with abiraterone were identified. Demographics, response variables and survival data were recorded.
RESULTS
Two-hundred and seventy-four patients received abiraterone, 114 (41.6%) after DES. Pre-chemotherapy abiraterone resulted in ≥50% PSA declines in 35/41 (85.4%) DES-naïve and 20/27 (74.1%) DES-treated patients. Post-docetaxel abiraterone resulted in ≥50% PSA declines in 40/113 (35.4%) DES-naïve and 23/81 (28.4%) DES-treated patients. Time to PSA progression was similar regardless of prior DES.
CONCLUSION
Abiraterone has important antitumour activity in men with CRPC even after DES exposure.
背景
阿比特龙是去势抵抗性前列腺癌（CRPC）患者的标准治疗方法。我们评估了阿比特龙在合成雌激素己烯雌酚（DES）之后的抗肿瘤活性。
方法
确定了接受阿比特龙治疗的去势抵抗性前列腺癌患者。记录了人口统计学、反应变量和生存数据。
结果
274 名患者接受了阿比特龙治疗，其中 114 名（41.6%）在 DES 之后。在化疗前使用阿比特龙，41 名 DES 初治患者中有 35 名（85.4%）和 27 名 DES 治疗患者中有 20 名（74.1%）出现 PSA 下降≥50%。在多西他赛后使用阿比特龙，113 名 DES 初治患者中有 40 名（35.4%）和 81 名 DES 治疗患者中有 23 名（28.4%）出现 PSA 下降≥50%。无论之前是否使用过 DES，PSA 进展时间均无差异。
结论
即使在 DES 暴露后，阿比特龙对 CRPC 男性也具有重要的抗肿瘤活性。
Zotero 插件